 |
Interleukin-2 |
|---|---|
| Trade Name | Teceleukin |
| Orphan Indication | In combination with interferon alfa-2a for the treatment of metastatic renal cell carcinoma |
| USA Market Approval | USA |
| USA Designation Date | 1990-05-03 00:00:00 |
| Sponsor | Hoffmann-La Roche, Inc.;340 Kingsland Street;Nutley, New Jersey, 07119 |
